Yung Zip Chemical Ind (4102) reported revenue of NT$40.1 million for Oct 2026, +15.3% year on year and +28.3% from the previous month. Revenue for Jan–Oct 2026 was NT$424.3 million (+7.4% year on year).
In Oct 2026, it ranked No. 108 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$40.1 million | +15.3% | +28.3% |
| Sep 2026 | NT$31.2 million | -12.2% | -11.6% |
| Aug 2026 | NT$35.3 million | +7.5% | -15.3% |
| Jul 2026 | NT$41.7 million | +16.7% | -37.9% |
| Jun 2026 | NT$67.1 million | +51.9% | +38.7% |
| May 2026 | NT$48.4 million | +27.7% | +29.9% |
| Apr 2026 | NT$37.3 million | -17.4% | -17.4% |
| Mar 2026 | NT$45.1 million | -9.2% | +75.4% |
| Feb 2026 | NT$25.7 million | -39.2% | -50.8% |
| Jan 2026 | NT$52.3 million | +41.6% | +12.6% |
| Dec 2025 | NT$46.4 million | +6.9% | +42.1% |
| Nov 2025 | NT$32.7 million | +2.5% | -5.9% |
| Oct 2025 | NT$34.7 million | +28.9% | -2.3% |
| Sep 2025 | NT$35.6 million | +2.7% | +8.2% |
| Aug 2025 | NT$32.9 million | -45.4% | -8.0% |
| Jul 2025 | NT$35.7 million | -42.2% | -19.2% |
| Jun 2025 | NT$44.2 million | +8.9% | +16.5% |
| May 2025 | NT$37.9 million | -44.4% | -16.0% |
| Apr 2025 | NT$45.1 million | -31.3% | -9.1% |
| Mar 2025 | NT$49.7 million | +4.2% | +17.4% |
| Feb 2025 | NT$42.3 million | +26.0% | +14.6% |
| Jan 2025 | NT$36.9 million | -46.4% | -15.0% |
| Dec 2024 | NT$43.4 million | -5.0% | +36.3% |
| Nov 2024 | NT$31.9 million | -54.7% | +18.3% |
| Oct 2024 | NT$27 million | -20.5% | -22.2% |
Jan–Oct 2026 cumulative: NT$424.3 million (+7.4% YoY)
Other Biotech & Medical companies
Compare with peers: Yung Zip Chemical Ind vs PEC / Yung Zip Chemical Ind vs Lotus Pharm / Yung Zip Chemical Ind vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16